|
Match
|
Document |
Document Title |
|
|
6774116 |
Prodrugs via acylation with cinnamate
A prodrug composition containing a cinnamate moiety and a biologically active molecule moiety which can be released by hydrolysis or activated by light is disclosed. The cinnamate moiety can have...
|
|
|
6770673 |
Therapeutic uses of arglabin in combination with other chemotherapy agents
Compositions and kits containing a first chemotherapeutic agent that includes arglabin or a derivative thereof and a second chemotherapeutic agent are described. The compositions and kits are...
|
|
|
6747012 |
Crystalline anthracycline antibiotic and process for producing the same
Disclosed are a crystalline form of anthracycline antibiotic having specific characteristic 2θ values as measured by the X-ray diffraction method, and a process for producing the crystalline form....
|
|
|
6747036 |
Methods of treating leukemia
The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective...
|
|
|
6733764 |
Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
The present invention comprises a method for the treatment of cancerous tumors in mammals comprising the administration of an effective amount of an immunostimulator which enhances and potentiates...
|
|
|
6720306 |
Tetrapartate prodrugs
A compound of Formula I, providing tetrapartate prodrugs is provided wherein: L 1 is a bifunctional linking moiety; D is a moiety that is a leaving group, or a residue of a compound to be...
|
|
|
6716821 |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
Cytotoxic agents bearing a polyethylene glycol (PEG) linking group having a terminal active ester, cytotoxic conjugates comprising one or more cytotoxic agents linked to a cell-binding agent via...
|
|
|
6709679 |
Antineoplastic conjugates of transferin, albumin and polyethylene glycol
Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at...
|
|
|
6706713 |
Conjugate for treating inflammatory infectious and/or skin diseases
This invention relates to the use of a conjugate comprising an active substance and a native protein which is not recognized as foreign protein for the production of a pharmaceutical preparation...
|
|
|
6703400 |
Methods for treating multidrug resistance
Methods are provided for treating multidrug resistance in refractory tumor cells comprising administering (1) a P-glycoprotein inhibitor in conjunction with (2) an antineoplastic agent.
|
|
|
6680300 |
Methods and compositions for the manufacture of highly potent anthracycline-based antitumor agents
The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moieties. These congeners show high activity in vitro against several tumor...
|
|
|
6677309 |
Anti-cancer drug aldehyde conjugate drugs with enhanced cytotoxicity compounds, compositions and methods
Monomeric and dimeric anti-cancer drug aldehyde conjugate compounds and pharmaceutically acceptable salts thereof. Specifically, monomeric and dimeric aldehyde conjugates of 1-2,...
|
|
|
6664233 |
Combination therapy including 9-nitro-20(S)-camptothecin and bleomycin
A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation such as cancer and restenosis is provided. The method comprises: delivering to the...
|
|
|
6653289 |
L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them
The present invention refers to compounds of general formula (I), the pharmaceutically acceptable salts thereof, the processes for their preparation, and the pharmaceutical compositions containing...
|
|
|
6642205 |
Methods and compositions for reducing side effects in chemotherapeutic treatments
A pharmaceutical compound and a process for making the compound is provided where the compound includes a therapeutic agent, a spacer and a galactose, the spacer being covalently linked to the...
|
|
|
6635677 |
Methoxyamine combinations in the treatment of cancer
This invention generally relates to novel compositions and methods for the treatment of certain cancers. Additionally, this invention relates to novel compositions and methods to screen drugs for...
|
|
|
6630454 |
Method and pharmaceutical composition for the treatment of cancer
A method of chemosensitization which comprises administering at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine to a subject in need thereof.
|
|
|
6624142 |
Trimethyl lock based tetrapartate prodrugs
The invention is directed primarily to compounds of Formula I: wherein: R 1 is a polymeric residue; L 1 is a bifunctional linking group; Y 1 and Y 2 are independently O, S or NR 7 ; R 2-7 ...
|
|
|
6593303 |
Anti-tumor synergetic composition
There are provided the combined use of 4-demethoxy-3′-deamino-3′-aziridinyl-4′-methansulfonyl
daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4′-methansulfonyl daunorubicin and an...
|
|
|
6582690 |
Process for treating tumors with cytotoxic substances
The invention concerns a cytotoxic, MDR-associated substance for producing a therapeutic agent for tumor therapy, which is characterized by a) the tumor cells of a tumor patient are chemosensitized...
|
|
|
6576638 |
Use of substance P antagonists in the treatment of the adenocarcinomas
It is described the use of antagonists of neuro kynin receptors (NK-1; substance P receptors) in order to establish a new drug effective in the treatment of adenocarcinomas, such antagonists being...
|
|
|
6541462 |
Sphingomyelin enhancement of tumor therapy
Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing...
|
|
|
6525100 |
Composition and method for treating peyronie's disease and related fibrotic tissue disorders
The invention is of a topical medicament and associated methodology for use thereof, through the use of which Peyronie's disease may be effectively, cost effectively, and painlessly treated. The...
|
|
|
6518252 |
Method of treating aquatic animals with an antimicrobial agent and chelating agent
The present invention relates to novel method of reducing microbial infections, especially bacterial infections, of animals, especially of aquatic animals such as fish maintained in tanks or...
|
|
|
6511966 |
Mitochondria protecting agents for treating mitochondria associated diseases
The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds,...
|
|
|
6506734 |
20(S) camptothecin glycoconjugates
The present invention relates to glycoconjugates of 20(S)-camptothecin, in which a 3-O-methylated β-L-fucose unit is linked to the 20-hydroxyl group of a camptothecin derivative via a...
|
|
|
6506765 |
Apomorphine derivatives and methods for their use
Apomorphine derivative compounds; pharmaceutically active compositions of apomorphine derivative compounds; and the use of apomorphine derivative compounds in methods for treating sexual...
|
|
|
6492335 |
Glycoconjugates from modified camptothecin derivatives (20-O-linkage)
The present invention relates to glycoconjugates of camptothecin derivatives in which at least one carbohydrate component is linked via suitable spacers with the 20-hydroxyl group of a camptothecin...
|
|
|
6468980 |
Methods and compositions for potentiating cancer chemotherapeutic agents
The effect of cancer chemotherapeutic agents is potentiated by combination with mineral ascorbates, Vitamin C metabolites and/or Vitamin C-derived furanones.
|
|
|
6462024 |
Use of inhibitors of the sodium-hydrogen exchanger for the production of a medicament for decreasing undesired effects of substrates of the heart
Inhibitors of the sodium-hydrogen exchanger are used for the production of a medicament for decreasing the undesired effects in human and in veterinary medicine which originate from substances...
|
|
|
6413937 |
Combinations for use in increasing the potency of a substrate for multidrug resistance related protein
A combination of an agent which is a substrate for multidrug resistance related protein (MRP) and an inhibitor of MRP which is a nonsteroidal anti-inflammatory drug (NSAID) or a structural analogue...
|
|
|
6407075 |
Fatty acid treatment
The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to...
|
|
|
6403563 |
Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
The combination of 4-demethoxy-3′-deamino-3′-aziridinyl-4′-methansulfonyl
daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4′-methansulfonyl daunorubicin together with an antineoplastic...
|
|
|
6399583 |
Hybrid anthracyclines from genetically engineered streptomyces galilaeus strains, process for production and uses thereof
The present invention relates to novel hybrid anthracyclines generated by cloning of fused genes in a mutated Streptomyces galilaeus strain DSM 11638. Said strain was obtained by mutagenization...
|
|
|
6387886 |
Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic
The present invention is directed to a method for the treatment of severe chronic bronchitis, i.e., bronchiectasis, using a concentrated aminoglycoside antibiotic formulation delivering the...
|
|
|
6376469 |
Crystalline amrubicin hydrochloride
β-Type crystalline amrubicin hydrochloride having a powder X-ray diffraction pattern having average values of diffraction angle(2θ) and relative intensity as given in the following table: ...
|
|
|
6372719 |
α&ngr β3 integrin antagonists in combination with chemotherapeutic agents
The present invention is directed to compounds of the formula and pharmaceutically acceptable salts and isomers thereof administered in combination with chemotherapeutic agents.
|
|
|
6369037 |
Controlled release of doxorubicin
A controlled release doxorubicin containing composition comprises doxorubicin physically entrapped in a dextran-methacrylate biodegradable hydrogel. The composition provides a rapid initial release...
|
|
|
6338859 |
Polymeric micelle compositions
Novel polymeric micelles which are used to deliver therapeutic agents, including anti tumor drugs.
|
|
|
6310039 |
Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at...
|
|
|
6303569 |
Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
The present invention is directed to double prodrugs containing polymeric-based transport forms. These polymeric compounds comprise the formula: ##STR1## wherein: B is H, OH, OSiR 13 , a...
|
|
|
6284747 |
Pharmaceutical formulation
Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The...
|
|
|
6284737 |
Methods of treatment with anthracycline derivatives
The present invention is a compound having the structure ##STR1## where: anthracycline is doxorubicin, daunorubicin or a derivative thereof; N is the 3' nitrogen of daunosamine; R a is H...
|
|
|
6277836 |
Methods and compositions for treating inflammatory bowel disease
The present invention provides a method and composition of medications use to treat inflammatory bowel disease. The invention further provides combinations of anti-atypical mycobacterial agents...
|
|
|
6274561 |
Antitumor agents comprising as the principal compounds containing silicon and nitrogen
Antitumor agent which comprises as the principal agent a mixture of organic compounds having amino group and silyl group (reffered to as silamines) and represented by structural formulae with...
|
|
|
6265385 |
Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy
The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method...
|
|
|
6258786 |
13-dihydro-3' aziridino anthracyclines
The present invention relates to anthracycline glycosides, to a process for their preparation and to pharmaceutical compositions containing the same.
|
|
|
6232294 |
Neuro-function regulatory agent
A neuro-function regulatory agent with lesser side effects, comprising glycosyl vitamin P as an effective ingredient. When administered to patients with nerve diseases, the agent exerts a...
|
|
|
6218369 |
Pharmaceutical compositions containing flavanolignanes and methods for using same as an antiproliferative
The invention relates to methods for preventing, inhibiting, or suppressing tumors by administering to a person in need of such treatment a therapeutically effective amount of one or more...
|
|
|
6214388 |
Immunoliposomes that optimize internalization into target cells
The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab'...
|